查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1917895

RNA分析市場－2026-2031年預測

RNA Analysis Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

RNA 分析市場預計將從 2025 年的 55.72 億美元成長到 2031 年的 112.69 億美元，複合年成長率為 12.45%。

RNA分析市場是生命科學和診斷產業中一個基礎且快速成長的細分市場，涵蓋了用於研究核糖核酸（RNA）分子的各種技術和調查方法。該市場對現代生物醫學研究至關重要，有助於理解基因表現、調控和功能。對編碼mRNA、非編碼RNA和複雜轉錄組的分析，能夠為細胞過程、疾病機制和治療標靶提供關鍵資訊。市場成長的驅動力在於其在許多高影響力領域發揮的關鍵作用，例如推進腫瘤學研究、應對感染疾病威脅、實現個人化醫療，以及推動蓬勃發展的基於RNA的治療發現和開發領域。

RNA分析在腫瘤學中扮演著至關重要的角色，是推動腫瘤學發展的重要且強大的因素。轉錄組學研究，例如RNA定序（RNA-Seq）技術，是癌症研究和精準腫瘤學的基礎。這些技術能夠識別疾病特異性基因表現特徵，發現用於診斷和預後的新型生物標記，並檢測驅動腫瘤發生的基因融合和剪接變異。這種分子譜分析對於理解腫瘤異質性和抗藥性機制以及開發標靶治療至關重要。持續嚴峻的全球癌症負擔導致對先進RNA分析工具的需求不斷成長，以支持基礎研究和臨床應用研究。

同時，感染疾病監測和疫情應對領域的應用正推動著強勁的市場成長動能。病原體RNA分析對於識別和表徵病毒、細菌和其他傳染性病原體、闡明其毒力和傳播機制以及追蹤基因組進化至關重要。這項能力在新冠肺炎疫情期間得到了充分展現，並且對於持續監測地方性流行病原體和新發病原體仍然至關重要。 RNA分析有助於疫苗研發、抗病毒藥物發現以及宿主-病原體相互作用的研究，使其成為全球公共衛生和研究機構的關鍵工具。

個人化醫療的快速發展是市場擴張的主要驅動力。向個人化醫療的轉變高度依賴分子數據。 RNA表現譜分析正被擴大用於患者分層、預測治療反應以及識別最有可能從特定標標靶治療或免疫療法中獲益的患者。這項應用在腫瘤學領域尤為突出，但正在擴展到其他治療領域，從而催生了對穩健、可重複且通常經過臨床檢驗的RNA分析平台的需求，這些平台能夠提供可操作的見解來指導治療決策。

或許最具活力的成長要素是基於RNA療法開發的爆炸性成長。 mRNA疫苗的成功應用證明了該平台的有效性，並刺激了對更廣泛的RNA藥物的大規模投資，包括治療性mRNA、 RNA干擾（RNAi）藥物、反義寡核苷酸以及依賴嚮導RNA的CRISPR技術。這些療法的整個生命週期，從標靶識別和檢驗到動態物標記評估和治療反應監測，都高度依賴先進的RNA分析技術。這直接推動了生物製藥研發過程中對分析工具、試劑和服務的需求。

此外，公共和私營部門對基礎研究和轉化研究的持續大規模投資也推動了市場發展。政府資助機構、學術機構和生物技術公司正在進行廣泛的研究，以揭示轉錄組的複雜性，了解健康和疾病狀態下的RNA生物學，並開發新的分析方法。這些研究工作通常得到國家和國際基因組學計劃的支持，確保了創新源源不斷，並帶動了RNA分析產品和服務的持續成長。

從地理位置來看，北美在市場中佔據主導地位。這一主導地位得益於許多主要學術研究中心的集中、強大的生物技術和製藥產業、充足的研發資金以及對尖端基因組技術的早期應用。該地區先進的臨床試驗和分子診斷基礎設施進一步鞏固了其作為RNA分析高級應用領先中心的地位，無論是在研究領域還是在臨床開發領域。

競爭格局包括成熟的生命科學工具公司、專業的基因組學公司和整合解決方案提供者。關鍵的競爭和創新領域集中在提高RNA-Seq平台的靈敏度、通量和多重定序能力，簡化和自動化樣品製備流程，降低單一樣本的成本，以及開發方便用戶使用的生物資訊軟體用於數據分析和解讀。提供從樣本製備到資料解讀的端到端解決方案的能力是關鍵的差異化優勢。

總之，RNA分析市場正經歷強勁成長，這得益於其在解決現代醫學和藥物研發中面臨的緊迫挑戰方面發揮的核心作用。其發展軌跡與精準醫學的進步和RNA療法的革命密切相關。未來市場發展將受到以下技術創新的影響：高品質轉錄組數據的普及化、臨床應用方法的標準化以及人工智慧在數據解讀中的持續應用。隨著我們對RNA生物學理解的不斷加深及其治療潛力的進一步挖掘，對先進、可靠且擴充性的RNA分析工具的需求將持續成長，從而鞏固其作為21世紀生物醫學研究重要支柱的地位。

本報告的主要優勢：

  • 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
  • 市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢，以及它們將如何塑造未來的市場發展。
  • 可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

您打算如何使用這份報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議
  • 正在研發中的產品

第4章 技術展望

第5章 RNA分析市場（按類型分類）

  • 介紹
  • 傳訊RNA（mRNA）
  • 轉移RNA（tRNA）
  • 其他

第6章 RNA分析市場：依應用領域分類

  • 介紹
  • 試劑
  • 成套工具
  • 酵素
  • 其他

第7章 RNA分析市場（按最終用戶分類）

  • 介紹
  • 製藥和生物技術公司
  • 學術和研究機構
  • 其他

第8章：按地區分類的RNA分析市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Promega Corporation
  • Lexogen
  • Zymo Research
  • Azenta US, Inc
  • Shimadzu
  • Cofactor Genomics
  • Parse Biosciences
  • CD Genomics
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615904

RNA Analysis Market, with a 12.45% CAGR, is projected to increase from USD 5.572 billion in 2025 to USD 11.269 billion in 2031.

The RNA analysis market is a foundational and rapidly expanding segment within the life sciences and diagnostics industry, encompassing a broad suite of technologies and methodologies for studying ribonucleic acid (RNA) molecules. This market is central to modern biomedical research, enabling the exploration of gene expression, regulation, and function. The analysis of coding mRNA, non-coding RNAs, and complex transcriptomes provides critical insights into cellular processes, disease mechanisms, and therapeutic targets. Market growth is propelled by its indispensable role in several high-impact areas: advancing oncology research, responding to infectious disease threats, enabling personalized medicine, and fueling the burgeoning field of RNA-based therapeutic discovery and development.

A primary and powerful driver is the critical role of RNA analysis in oncology. The study of the transcriptome through techniques like RNA sequencing (RNA-Seq) is fundamental to cancer research and precision oncology. It enables the identification of disease-specific gene expression signatures, the discovery of novel biomarkers for diagnosis and prognosis, and the detection of fusion genes and splice variants that drive tumorigenesis. This molecular profiling is essential for understanding tumor heterogeneity, mechanisms of drug resistance, and for developing targeted therapies. The persistent and significant global burden of cancer ensures sustained and growing demand for sophisticated RNA analysis tools to support both basic research and clinical translational efforts.

Concurrently, the market is strongly driven by its application in infectious disease research and outbreak response. The analysis of pathogen RNA is crucial for identifying and characterizing viruses, bacteria, and other infectious agents, understanding their virulence and transmission mechanisms, and tracking genomic evolution. This capability was prominently demonstrated during the COVID-19 pandemic and remains vital for ongoing surveillance of endemic and emerging pathogens. RNA analysis supports vaccine development, antiviral drug discovery, and the study of host-pathogen interactions, making it a critical tool for public health agencies and research institutions worldwide.

The accelerating focus on personalized medicine is a major catalyst for market expansion. The shift toward tailoring medical treatment to the individual characteristics of each patient relies heavily on molecular data. RNA expression profiling is increasingly used to stratify patients, predict treatment response, and identify those most likely to benefit from specific targeted therapies or immunotherapies. This application, particularly prominent in oncology but expanding to other therapeutic areas, creates demand for robust, reproducible, and often clinically validated RNA analysis platforms that can deliver actionable insights to guide therapeutic decisions.

Perhaps the most dynamic growth vector is the explosion in RNA-based therapeutic development. The successful deployment of mRNA vaccines has validated the platform and catalyzed massive investment in a broader spectrum of RNA medicines, including therapeutic mRNAs, RNA interference (RNAi) drugs, antisense oligonucleotides, and CRISPR-based technologies reliant on guide RNAs. The entire lifecycle of these therapeutics-from target identification and validation to pharmacodynamic biomarker assessment and monitoring treatment response-is deeply dependent on advanced RNA analysis. This directly fuels demand for analytical tools, reagents, and services across the biopharmaceutical R&D continuum.

Furthermore, the market benefits from substantial and sustained investment in basic and translational research from both public and private sectors. Government funding agencies, academic institutions, and biotechnology companies are conducting extensive research to unravel the complexities of the transcriptome, understand RNA biology in health and disease, and develop novel analytical methods. These initiatives, often supported by national and international genomics programs, ensure a continuous pipeline of innovation and a high volume of consumption for RNA analysis products and services.

Geographically, North America maintains a dominant market position. This leadership is underpinned by a concentration of leading academic research centers, a robust biotechnology and pharmaceutical sector, substantial R&D funding, and early adoption of cutting-edge genomic technologies. The region's well-developed infrastructure for clinical trials and molecular diagnostics further reinforces its role as the primary hub for advanced RNA analysis applications in both research and developing clinical contexts.

The competitive landscape includes established life science tools companies, specialized genomics firms, and providers of integrated solutions. Key areas of competition and innovation focus on improving the sensitivity, throughput, and multiplexing capabilities of RNA-Seq platforms; simplifying and automating library preparation workflows; reducing costs per sample; and developing user-friendly bioinformatics software for data analysis and interpretation. The ability to offer end-to-end solutions-from sample preparation to data insight-is a significant differentiator.

In conclusion, the RNA analysis market is experiencing robust growth fueled by its central role in addressing some of the most pressing challenges in modern medicine and drug discovery. Its trajectory is inextricably linked to the progress of precision medicine and the RNA therapeutic revolution. Future market development will be shaped by technological advancements that democratize access to high-quality transcriptomic data, the standardization of methods for clinical application, and the continued integration of artificial intelligence for data interpretation. As our understanding of RNA biology deepens and its therapeutic potential is further unlocked, the demand for sophisticated, reliable, and scalable RNA analysis tools will continue to expand, solidifying its status as an essential pillar of 21st-century biomedical science.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

RNA Analysis Market Segmentation

  • By Type
  • Messenger RNA (mRNA)
  • Transfer RNA (tRNA)
  • Others
  • By Application
  • Reagnet
  • Kits
  • Enzymes
  • Others
  • By End-User
  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations
  • 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. RNA ANALYSIS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Messenger RNA (mRNA)
  • 5.3. Transfer RNA (tRNA)
  • 5.4. Others

6. RNA ANALYSIS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Reagnet
  • 6.3. Kits
  • 6.4. Enzymes
  • 6.5. Others

7. RNA ANALYSIS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical & Biotech Companies
  • 7.3. Academic & Research Institutes
  • 7.4. Others

8. RNA ANALYSIS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Promega Corporation
  • 10.2. Lexogen
  • 10.3. Zymo Research
  • 10.4. Azenta US, Inc
  • 10.5. Shimadzu
  • 10.6. Cofactor Genomics
  • 10.7. Parse Biosciences
  • 10.8. CD Genomics
  • 10.9. Thermo Fisher Scientific Inc.
  • 10.10. Illumina, Inc.
  • 10.11. F. Hoffmann-La Roche Ltd
  • 10.12. QIAGEN
  • 10.13. Bio-Rad Laboratories, Inc.
  • 10.14. Danaher Corporation
  • 10.15. Agilent Technologies, Inc

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations